By Dr. Yahia Anane, PhD

Blood clots are the second leading cause of death in cancer patients — after cancer itself. And most patients are never told why their blood is trying to kill them.

Here is the biology of what is actually happening, why it matters, and what you can do about it.

Introduction

Cancer does not just grow tumors. It hijacks your entire clotting system — turning your own blood into a weapon that protects cancer cells, promotes metastasis, and can kill you through a pulmonary embolism before the cancer itself does.

The numbers:

• Up to 20% of cancer patients will develop a blood clot
• The risk is 7 to 12 times higher than the general population
• For certain cancers — pancreatic, brain, ovarian — the risk is up to 28-fold higher

📄 Khorana AA. Epidemiology and pathophysiology of cancer-associated thrombosis. British Journal of Cancer, 2010. 🔗 https://www.nature.com/articles/6605599

This is not a side issue. It is central to cancer survival, metastasis, and immune evasion.

How Cancer Hijacks Your Clotting System

1. Tissue Factor — cancer’s clotting trigger

Cancer cells produce and release Tissue Factor — the primary molecule that initiates the entire clotting cascade in your body.

Tissue Factor activates Factor Xa and thrombin, generating fibrin clots directly in your bloodstream.

But Tissue Factor does not just cause clots. It also directly promotes tumor angiogenesis, tumor growth, and metastasis through protease-activated receptors on the surface of cancer cells. In other words, the same molecule that clogs your veins also feeds the tumor.

📄 Falanga A et al. Mechanisms of cancer-induced thrombosis. Thrombosis Research, 2007. 🔗 https://pubmed.ncbi.nlm.nih.gov/16855354/

2. Platelet cloaking — shielding circulating tumor cells

Activated platelets physically wrap around circulating tumor cells — hiding them from NK cells and T cells as they travel toward distant organs.

This is not just a clotting problem. It is a metastasis engine. Every clot-favoring change in your blood is also making it easier for cancer to spread.

The 2025 Nature paper on aspirin showed that platelet-derived thromboxane A2 also paralyzes T cells at distant sites — meaning platelets shield tumor cells physically and disable the immune system that would otherwise destroy them.

3. Tumor-shed microparticles

Cancer cells release procoagulant microparticles into the bloodstream — tiny membrane fragments loaded with Tissue Factor. These microparticles travel throughout the body and activate clotting at distant sites, even far from the primary tumor.

This is why cancer clots so often appear in unexpected places — lungs, legs, brain, mesenteric veins. The signal is coming from all directions at once.

📄 Falanga A et al. Mechanisms and risk factors of thrombosis in cancer. Critical Reviews in Oncology/Hematology, 2017. 🔗 https://pubmed.ncbi.nlm.nih.gov/28917273/

4. Chemotherapy makes it worse

Chemotherapy itself increases clotting risk through three mechanisms:

• Endothelial damage — the inner lining of your blood vessels becomes injured and pro-clotting
• Platelet activation — chemo agents directly activate platelets
• Reduced natural anticoagulant proteins — Protein C, Protein S, and antithrombin all decline

Surgery and immobility during treatment compound this further. A cancer patient recovering in bed after chemotherapy is in one of the highest-risk situations for clot formation of any patient in medicine.

D-Dimer — The Marker to Watch

D-dimer is a fibrin degradation product — a fragment released when your body is forming and breaking down blood clots. In a healthy person, D-dimer is very low.

In cancer patients, D-dimer is often chronically elevated — and the higher it is, the worse the prognosis:

• Elevated D-dimer is directly associated with worse overall survival
• It correlates with higher metastatic burden
• It predicts increased risk of venous thromboembolism (VTE)

This is not just a clot marker. It is a cancer activity marker. It reflects how much your body is currently dealing with tumor-driven coagulation.

Test it regularly — every 4 to 8 weeks — alongside:

• PLR — Platelet-to-Lymphocyte Ratio
• NLR — Neutrophil-to-Lymphocyte Ratio
• LMR — Lymphocyte-to-Monocyte Ratio
• Fibrinogen — another clotting marker often elevated in cancer
• Full CBC and platelet count

These markers cost pennies to run and give you real-time information about your body’s clotting state.

What Actually Helps

Baby Aspirin

Aspirin irreversibly blocks COX-1 and thromboxane A2 in platelets. Because platelets cannot regenerate this enzyme, a single low daily dose keeps platelets suppressed for their entire 7 to 10-day lifespan.

This does three things at once: reduces clotting, disrupts platelet cloaking of tumor cells, and blocks the TXA2-driven T cell paralysis discovered in 2025.

Typical dose: 75 to 100 mg daily, with food, indefinitely. Uncoated is preferred over enteric-coated for reliable platelet suppression.

If you are on other blood thinners or have a bleeding history, discuss with your clinician first.

Nattokinase

Nattokinase is a fibrinolytic enzyme derived from fermented soybeans. It directly breaks down fibrin — the protein scaffold that holds clots together — and measurably reduces D-dimer levels.

It also has anti-inflammatory effects and lowers blood viscosity, both of which reduce cancer’s ability to form microclots around tumor cells.

Typical dose: 2000 to 4000 FU (fibrin units), 1 to 2 times per day, on an empty stomach. Higher doses (up to 6000 FU) are used in patients with elevated D-dimer or history of clots.

Serrapeptase and Lumbrokinase

Two other fibrinolytic enzymes worth knowing:

• Serrapeptase — 40,000 to 120,000 units daily, empty stomach. Also reduces inflammation and scar tissue.
• Lumbrokinase — derived from earthworm extract, the most potent natural fibrinolytic known. 20 to 40 mg daily, empty stomach. Used in patients with the highest clotting risk.

These can be used alone or in combination with nattokinase, rotated in cycles.

Omega-3 Fatty Acids

Omega-3 (especially EPA) reduces platelet aggregation and lowers the inflammatory cytokines (IL-6, TNF-α) that drive hypercoagulability. It also reduces fibrinogen and blood viscosity over time.

Typical dose: 2 to 4 grams per day of combined EPA and DHA, with meals.

Curcumin

Curcumin has documented anti-platelet, anti-thrombin, and fibrinolytic effects. It is one of the most versatile compounds in the entire cancer protocol — and its blood-thinning contribution is often overlooked.

Typical dose: 500 to 1000 mg twice daily, in a bioavailable form (liposomal, phytosome, or with piperine).

Bromelain, Garlic, and Ginger

Three natural anti-platelet agents that support the overall strategy:

• Bromelain — 500 mg twice daily, empty stomach. Also improves nattokinase absorption.
• Aged garlic extract — 600 to 1200 mg daily
• Ginger — fresh or as extract, 500 to 2000 mg daily

Exercise and Movement

Venous stasis — pooling of blood in the legs from lack of movement — is one of the primary clot triggers in cancer patients, especially after chemotherapy sessions or hospital stays.

Daily movement is not optional:

• Walk every 1 to 2 hours during the day
• Rebounding for 10 to 20 minutes daily (moves lymph and returns blood from the legs)
• Basic resistance training 2 to 3 times per week
• Calf raises and ankle circles during long sitting periods

Movement is the single most powerful natural anti-clotting tool available.

Hydration

Dehydration thickens the blood significantly and increases clotting risk. Most cancer patients are chronically underhydrated — from medications, reduced thirst, or nausea.

Target: 2 to 3 liters of clean, filtered water per day. Add electrolytes (sodium, potassium, magnesium) if you sweat, exercise, or are on diuretics.

The Bottom Line

Cancer does not just grow tumors. It turns your blood into a weapon.

• Blood clots are the second leading cause of death in cancer patients
• Your clotting system is central to metastasis, immune evasion, and survival
• Monitor your D-dimer, PLR, NLR, LMR, and fibrinogen regularly
• Take baby aspirin (if no bleeding contraindications)
• Support fibrinolysis with nattokinase, serrapeptase, or lumbrokinase
• Add omega-3, curcumin, bromelain, garlic, ginger for compounding effect
• Move daily — venous stasis is a killer
• Stay hydrated — 2 to 3 liters of clean water daily

This is not optional. It is life-saving.

The cancer patients who track their clotting biology and address it early live longer than those who ignore it. The ones who do not — regardless of how well their tumor treatment is going — remain at high risk of dying from something that could have been prevented.

Watch the blood. Support the fibrinolysis. Keep the body moving.

Dr. Yahia Anane, PhD — drananeyahia.com